Pacer Advisors
CRBP icon

Pacer Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Pacer Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-132
Closed -$5.97K – 2591
2024
Q2 		$5.97K Buy
+132
New +$5.55K ﹤0.01% 3620
2020
Q4 		– Sell
-117
Closed -$6K – 1511
2020
Q3 		$6K Buy
+117
New +$21.2K ﹤0.01% 1376

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Pacer Advisors's CRBP Position: Q3 2024 in Review

Pacer Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 132 shares — an estimated $5.97K sold.

Pacer Advisors first reported a position in CRBP in Q3 2020 and held it in 2 quarters. The position peaked at $6K in Q3 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Pacer Advisors reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 132 Corbus Pharmaceuticals shares in Q3 2024, an estimated $5.97K.
  • Pacer Advisors first reported a position in Corbus Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Pacer Advisors's Corbus Pharmaceuticals position peaked at $6K in Q3 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.